Why is My Genetic Blood Test Negative for MELAS?
At a Glance
A negative blood test does not rule out MELAS. Because blood cells turn over rapidly, the body naturally filters out cells with mutated mitochondria over time, causing false negatives. Testing tissues that don't replace themselves quickly, like urine sediment or muscle biopsies, is more accurate.
In this answer
3 sections
It can be incredibly confusing and frustrating to have a doctor strongly suspect you have MELAS, only for your genetic blood test to come back “negative.” The reason this happens involves how mitochondrial DNA behaves in the body. Unlike your regular DNA, which is essentially identical in every cell, the percentage of abnormal mitochondrial DNA varies depending on the tissue being tested [1]. In parts of the body where cells divide and replace themselves rapidly—like the blood—cells carrying mutated mitochondria are often filtered out or outcompeted by healthy cells over time [2]. As a result, the mutation might drop below detectable levels in your bloodstream, leading to a false-negative test result even when the disease is actively affecting other parts of your body [3].
The Mix of Healthy and Mutated Mitochondria
To understand why tests can vary, it helps to understand a concept called heteroplasmy. Every cell in your body contains hundreds to thousands of mitochondria. In someone with MELAS, each cell holds a mixture of both healthy, normal mitochondria and mitochondria with a genetic mutation (most commonly seen on lab reports as the m.3243A>G mutation) [4].
This mix is not perfectly balanced. The proportion of mutated mitochondria varies significantly from one tissue type to another, and even from one cell to another within the same tissue [1]. This unequal distribution means that testing one part of the body might give a completely different result than testing another part [5].
Why Blood “Flushes Out” the Mutation
Blood cells have a very high turnover rate, meaning they are constantly dividing, dying off, and being replaced by new cells.
As your body generates new blood cells, there is a natural “purifying” process. Your body’s blood-producing systems tend to select against cells that have high levels of mutated mitochondria, favoring healthier cells instead [2][6]. Because of this natural sorting mechanism, the percentage of mutated mitochondrial DNA in the bloodstream gradually decreases as you get older [7].
This makes blood an unreliable long-term indicator for MELAS. A patient might have a high enough mutation load to cause severe neurological or muscular symptoms, while simultaneously having a mutation level in their blood that is so low it evades detection [3].
Finding the Mutation: Alternative Testing
If your doctor’s clinical suspicion for MELAS remains high despite a negative blood test, they will likely recommend testing tissues that do not undergo rapid cell division. Because these cells do not constantly replace themselves, they hold onto the mutated mitochondria much longer [8][9].
There are two primary alternatives to blood testing:
- Urine Sediment Analysis: This is often the best next step. When you provide a urine sample, it contains epithelial cells that have naturally shed from the lining of your urinary tract. Because these cells do not undergo the same strict “weeding out” or purifying process as blood cells, they provide a much higher and more stable measure of the mutation [10][11]. This test is completely non-invasive—often as simple as providing a sample in a cup at the lab—and is frequently more sensitive and reliable than a blood test [3].
- Muscle Biopsy: Skeletal muscles require enormous amounts of energy and are made of cells that do not frequently divide (post-mitotic cells). For these reasons, muscle tissue tends to accumulate and retain high levels of mutant mitochondrial DNA [4][12]. While this requires a minor surgical procedure to remove a small piece of muscle, it is highly accurate and provides conclusive evidence of a mitochondrial disorder [3]. Skin biopsies (which look at cells called fibroblasts) may also be used for similar reasons [10].
A negative blood test does not rule out MELAS. It simply means the investigation needs to shift to a different part of the body.
Common questions in this guide
Why was my genetic blood test for MELAS negative if I have symptoms?
What is heteroplasmy in MELAS testing?
If my blood test is negative, how else can I be tested for MELAS?
Why is a urine test sometimes better than a blood test for MELAS?
Will I need a muscle biopsy to diagnose MELAS?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Given my negative blood test but ongoing symptoms, should we order a urine sediment analysis to check for the m.3243A>G mutation?
- 2.If the urine test is also negative or inconclusive, would a muscle or skin biopsy be the next best step for my specific case?
- 3.Are there local labs equipped to perform specialized mitochondrial testing on urine or muscle samples, or will these need to be sent out to a specialty clinic?
- 4.How does the lab's detection threshold for heteroplasmy affect my results, and what is the lowest percentage of mutated DNA they can detect?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (12)
- 1
Mitochondrial cytopathy with common MELAS mutation presenting as multiple system atrophy mimic.
Pröbstel AK, Schaller A, Lieb J, et al.
Neurology. Genetics 2016; (2(6)):e121 doi:10.1212/NXG.0000000000000121.
PMID: 27878137 - 2
T cell activation contributes to purifying selection against the MELAS-associated m.3243A>G pathogenic variant in blood.
Walker MA, Li S, Livak KJ, et al.
Journal of inherited metabolic disease 2024; (47(4)):757-765 doi:10.1002/jimd.12726.
PMID: 38499449 - 3
Prediction of long-term prognosis by heteroplasmy levels of the m.3243A>G mutation in patients with the mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes syndrome.
Fayssoil A, Laforêt P, Bougouin W, et al.
European journal of neurology 2017; (24(2)):255-261 doi:10.1111/ene.13176.
PMID: 27869334 - 4
Resolving complexity in mitochondrial disease: Towards precision medicine.
Boggan RM, Lim A, Taylor RW, et al.
Molecular genetics and metabolism 2019; (128(1-2)):19-29 doi:10.1016/j.ymgme.2019.09.003.
PMID: 31648942 - 5
Proton spectroscopy: a simple and useful tool in the investigation of mitochondrial disease.
Nassif DV, Vasconcellos LFR
Arquivos de neuro-psiquiatria 2022; (80(5)):543-544 doi:10.1590/0004-282X-ANP-2021-0422.
PMID: 35486820 - 6
Lecocytes mutation load declines with age in carriers of the m.3243A>G mutation: A 10-year Prospective Cohort.
Langdahl JH, Larsen M, Frost M, et al.
Clinical genetics 2018; (93(4)):925-928 doi:10.1111/cge.13201.
PMID: 29266179 - 7
mtDNA heteroplasmy level and copy number indicate disease burden in m.3243A>G mitochondrial disease.
Grady JP, Pickett SJ, Ng YS, et al.
EMBO molecular medicine 2018; (10(6)) doi:10.15252/emmm.201708262.
PMID: 29735722 - 8
The Mitochondrial m.3243A>G Mutation on the Dish, Lessons from In Vitro Models.
Ryytty S, Hämäläinen RH
International journal of molecular sciences 2023; (24(17)) doi:10.3390/ijms241713478.
PMID: 37686280 - 9
Quantitative Variation in m.3243A > G Mutation Produce Discrete Changes in Energy Metabolism.
McMillan RP, Stewart S, Budnick JA, et al.
Scientific reports 2019; (9(1)):5752 doi:10.1038/s41598-019-42262-2.
PMID: 30962477 - 10
Prognostication in MELAS syndrome and other m.3243A-G mutation-associated disorders.
Pinto WB, Souza PV, Oliveira AS
European journal of neurology 2017; (24(2)):231-232 doi:10.1111/ene.13211.
PMID: 28000982 - 11
One mutation, three phenotypes: novel metabolic insights on MELAS, MIDD and myopathy caused by the m.3243A > G mutation.
Esterhuizen K, Lindeque JZ, Mason S, et al.
Metabolomics : Official journal of the Metabolomic Society 2021; (17(1)):10 doi:10.1007/s11306-020-01769-w.
PMID: 33438095 - 12
This page explains mitochondrial DNA testing and heteroplasmy for educational purposes. Always consult your neurologist or geneticist to determine the best diagnostic testing strategy for your specific symptoms.
Get notified when new evidence is published on MELAS.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.